AzTrials
AzTrials

Covid19 PneumoniaCOVISQARNCT04881214

COVID-19 Pneumonia: Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program

A study testing Pulmonary rehabilitation in people with Covid19 Pneumonia and Chronic Thromboembolic Pulmonary Hypertension, run by University Hospital, Geneva at 1 site in Switzerland.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The pathophysiological processes involved in COVID-19 pneumonia are not fully understood. Specific alterations of the airways, lung parenchyma and pulmonary vascular tree could explain a severe ventilation/perfusion heterogeneity resulting in severe hypoxemia during the active phase of the disease. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Pulmonary rehabilitation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteSwitzerland
Study dates
1 Jul 2020to 30 Jun 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Patients will be eligible for inclusion if they fulfil all the following criteria:

  • Patients aged ≥ 18 years.
  • Confirmed diagnosis of SARS-Cov-2 infection by nasal swab, other viral sample (i.e. sputum, bronchoalveolar lavage) or Chest imaging suggestive of SARS-CoV-2 pneumonia (Chest X-ray or CT-scan).
  • Requirement for oxygen supplementation.
  • Persistent respiratory symptoms (i.e. dyspnoea, cough) or asthenia.
  • Abnormal 6MWT at 3 months (distance < 90% predicted or desaturation ≥ 3% or Borg >5) and/or abnormal lung function as described by the international recommendations

Patients will be excluded if they:

  • Already had existing severe and symptomatic pulmonary condition before COVID-19 pneumonia
  • Are unable to execute the different tests and surveys because of cognitive or physical limitations.
  • Are already included in a structured rehabilitation program
  • Have comorbidities with a life expectancy of less than 12 months.
  • Any relevant acute medical disorder/acute disease state judged by the investigators as likely to represent a risk for the patient to fulfil a rehabilitation program or requiring urgent investigations.

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • Hôpitaux Universitaires de Genève

    Geneva, 1205

Other trials in Switzerland

About this study

Official title: Impact of COVID-19 Pneumonia on Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program (COVISQAR)

The pathophysiological processes involved in COVID-19 pneumonia are not fully understood. Specific alterations of the airways, lung parenchyma and pulmonary vascular tree could explain a severe ventilation/perfusion heterogeneity resulting in severe hypoxemia during the active phase of the disease. Additional skeletal muscle impairment related to systemic inflammation may also explain persisting symptoms in the follow-up phase. The first aim of the present project is to explore these different processes by evaluating the impact of the COVID-19 pneumonia on exercise capacity, pulmonary function and perfusion by a physiological and radiologic study. An ambulatory pulmonary rehabilitation will also be studied to assess its impact on the physiological parameter mentioned and the health-related quality of life questionnaire as a potential long-term treatment. The investigators propose a single center randomized controlled study at the University Hospitals of Geneva. 60 adult patients having suffered a hypoxemic COVID-19 pneumonia with persistent symptoms at 3-months after hospital discharge will be included. A functional and physiological study will be performed, including a six-minute walk test, pulmonary function testing, diffusing capacity for carbon monoxide, maximal inspiratory pressure and sniff nasal inspiratory pressure. Those with at least one abnormal value will be invited to fill the Saint Georges Respiratory Questionnaire, the Short Form 36 and the Hospital Anxiety and Depression Scale and will undergo a chest dual energy computed tomography (DECT), a cardiopulmonary exercise testing with non-invasive cardiac output and stroke volume evaluation and an evaluation of the pulmonary shunt by hyperoxia (100% oxygen breathing) at rest and during light effort. Then patients will be randomized on a 1:1 basis for pulmonary rehabilitation program or usual care. All work-up except DECT will be repeated at 6 and 12 months after hospital discharge. The investigators hypothesize that our study will allow a better understanding of pathophysiological mechanisms involved in COVID-19. This will potentially determine therapeutic target for patients with persisting symptoms and functional decay after COVID-19. The investigators also expect to see an improvement of exercise capacity and physiological parameters in the pulmonary rehabilitation group, as compared to the control group, suggesting pulmonary rehabilitation as a possible long-term treatment of this condition.

Read the detailed description

COVID-19 is an emerging pandemic disease caused by a novel coronavirus (SARS-CoV-2) since December 2019. This condition may be associated with a severe pneumonia and an acute respiratory distress syndrome (ARDS) resulting in a high mortality and morbidity.A standardized follow up of COVID-19 patients after discharge from Geneva University Hospitals (Covicare) was implemented since March 29th 2020 by the divisions of infectious disease and respiratory medicine, in association with the primary care medicine department. A follow-up is ensured until one month after discharge. All patients are registered in a database (REDCapTM,Tennessee, USA).

The pathophysiological mechanisms of ARDS in COVID-19 and its long-term consequences on respiratory and cardiovascular systems remain unclear. Several histopathological studies have demonstrated occurrence of interstitial lung disease. Furthermore, there are some reports of associated endothelitis, thrombosis in the microcirculation5 and a high prevalence of venous thrombo-embolic events in ICU admitted patients, with pulmonary embolism accounting for 85% of those events.Both these changes contribute to increase heterogeneity of ventilation - perfusion ratio (VA/Q), thereby widening the alveolar - arterial oxygen gradient, and thus causing serious hypoxaemia, with remarkable fall of arterial oxygen saturation (SaO2). Finally, the interstitial pneumopathy may cause a persisting reduction of lung diffusing capacity for carbon monoxide (DLCO), further decreasing SaO2 even after recovery from COVID-19 pneumonia.

Chest Dual-Energy Computed Tomography (DECT) enables a combined functional and morphological analysis of the lung in a single and simple acquisition. Because of the attenuation properties of iodine at two different photon energies (80 and 140kV), DECT is able to reveal pulmonary blood volume distribution and generate color-coded pulmonary iodine volume maps, corresponding to the pulmonary perfusion. These pulmonary perfusion maps allow a qualitative analysis of the perfusion.Furthermore, the iodine concentration of the lung confers an objective and quantitative regional analysis of the perfusion. In comparison with a conventional CT, no additional intravenous iodine contrast medium injection or radiation doses are needed; a functional image processing is simply added. We recently demonstrated how DECT may help to define lung perfusion changes after therapeutic measures in patients with chronic obstructive pulmonary disease. Moreover, DECT offers an excellent correlation with perfusion scintigraphy (V/Q scan). DECT also offers a superior anatomic and functional comprehension by simultaneously recording the vascular anatomy, parenchymal morphology, and functional perfusion. Consequently, DECT may provide important information both on persisting parenchymal and perfusion alteration after COVID-19.

In addition to the pulmonary component, the systemic inflammation state due to the concurring "cytokine storm syndrome" may have an important role in the development of neuromuscular alterations, independently of direct consequences of hospitalization in intensive care unit. Neuromuscular alterations concur with lung function impairment in compromising the functional state of the patient. As a consequence, we ought to expect a reduction of physical exercise capacity, which is normally determined by a VO2max measurement during cardiopulmonary exercise test (CPET) and by means of the six-minute walk test (6MWT).

Moreover, it is well described that ARDS is associated with a significant long-term morbidity. At one year, 80% of ARDS survivors have a reduced diffusing capacity and 20% suffer from an airflow obstruction. 35% of patients have an exercise limitation based on the 6MWT at two years. Moreover, impairment in lung function, musculoskeletal dysfunction and functional limitation are linked to health-related quality of life (HRQL) decrement.

Studies from a cohort of patients who suffered from ARDS due to SARS-CoV-1 in 2002 showed a positive correlation between lung function and the HRQL physical functioning domain. Distance performed during 6MWT correlated also with almost all Short Form Health Survey-36 (SF-36) domains. Furthermore, mood disorders are commonly described in ARDS survivors, with studies reporting up to 50% of depression at one year in this population. Depression and anxiety are themselves associated with lower HRQL scores.

Pulmonary rehabilitation has been shown to improve HRQL, maximal exercise capacity and 6MWD in chronic pulmonary disease. It was also shown that 2 months of ambulatory pulmonary rehabilitation improved pulmonary function and the St. George's Respiratory Questionnaire (SGRQ) at 3 and 6 months post-discharge following recovery from ARDS due to severe influenza A (H1N1 in 2009) pneumonitis.

The purpose of this study is 1/ to explore the long-term impact of COVID-19 on physiological respiratory parameters, functional capacity, HRQL and mood disturbances ; 2/ to assess the benefit of a pulmonary rehabilitation program on these outcomes through a randomized-control study, and 3/ to determine the contribution of DECT to the understanding of the pathophysiological alterations in patients with functional sequelae of COVID-19 infection.

Being tested
Pulmonary rehabilitation
Keywords
COVID-19, cardiopulmonary rehabilitation, spirometry, thromboembolic disease, non-invasive cardiac output
Medical subject headings
Muscular Diseases, COVID-19, Thromboembolism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pulmonary rehabilitationOther

    pulmonary rehabilitation for 12 weeks, 3 times a week. control will take place at 3, 6 and 12 months

Study groups in NCT04881214
Study groupRoleWhat they receive
ControlNo interventionPatients in this arm will receive standard of care
Pulmonary RehabilitationExperimentalPatients will undergo a 12-weeks Pulmonary rehabilitation program. It will include 3 sessions of supervised exercise per week, as initially proposed on COPD patients. Patients will exercise on electromagnetically braked cycle ergometers for 45 min by alternating 30-s exercise intervals at 100% of peak-work rate estimated during the initial incremental test, with 30-s rest periods. Total workload will be increased (by 5%) on a weekly basis. Strength training of lower and upper limbs, will also be included.
Receives: Other: Pulmonary rehabilitation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Effect of ambulatory pulmonary rehabilitation in health related quality of life

    St George's Respiratory questionnaire change (units). Scores range from 0 to 100, with higher scores indicating more limitations

    Measured: 12 months

Secondary outcomes (18)
  1. Long-term consequences of COVID-19 pneumonia on VEMS

    Change in VEMS (L, % predicted)

    Measured: 12 months

  2. Long-term consequences of COVID-19 pneumonia on Vital Capacity

    Change in Vital Capacity (L, % predicted)

    Measured: 12 months

  3. Long-term consequences of COVID-19 pneumonia on Total Lung Capacity

    Change in Total Lung Capacity (L, % predicted)

    Measured: 12 months

  4. Long-term consequences of COVID-19 pneumonia on diffusion capacity of CO

    Change in diffusion capacity of CO (ml/min/kPa, % predicted)

    Measured: 12 months

  5. long-term consequences of COVID-19 pneumonia on Vital Capacity (VC)

    absolute value (liters) measured at inclusion and at the end of the study period with spirometry

    Measured: 12 months

  6. long-term consequences of COVID-19 pneumonia on total lung capacity (TLC)

    absolute value (liters) measured at inclusion and at the end of the study period with plethysmography

    Measured: 12 months

  7. long-term consequences of COVID-19 pneumonia on diffusing capacity for carbon monoxide (DLCO)

    absolute value (ml/min/kPa) measured at inclusion and at the end of the study period with plethysmography

    Measured: 12 months

  8. Incidence of interstitial lung disease and/or images suggestive of abnormalities in the pulmonary circulation.

    Evaluated with a chest dual energy Computed Tomography: presence of honeycombing, bronchiectasis or acute or chronic thromboembolism.

    Measured: 3 months

  9. Effect of COVID-19 pneumonia on The Short Form 36 (SF-36) questionnaire score

    measured at inclusion and at the end of the study. Score from 0 (poor health) to 100 (perfect health)

    Measured: 12 months

  10. Effect of COVID-19 pneumonia on Hospital Anxiety and Depression Scale (HADS) score

    measured at inclusion and at the end of the study. . Each of them is coded From 0 to 3, with a score varying from 0 to 21

    Measured: 12 months

  11. Effect of pulmonary rehabilitation in VO2 max during cardiopulmonary exercise testing (CPET)

    Change in VO2 max (ml/min/kg)

    Measured: 3,6 and 12 months

  12. Effect of pulmonary rehabilitation in power during cardiopulmonary exercise testing (CPET)

    Change in power max (Watts)

    Measured: 3,6 and 12 months

  13. Effect of pulmonary rehabilitation in ventilation during cardiopulmonary exercise testing (CPET)

    Change in ventilation (L/min)

    Measured: 3,6 and 12 months

  14. Effect of pulmonary rehabilitation in Tidal Volume during cardiopulmonary exercise testing (CPET)

    Change in Tidal Volume (L)

    Measured: 3,6 and 12 months

  15. Effect of pulmonary rehabilitation in 6 minutes walk test distance

    Change in meters

    Measured: 3,6 and 12 months

  16. Effect of pulmonary rehabilitation in 6 minutes walk test dyspnea

    Change in self reported Borg dyspnea

    Measured: 3,6 and 12 months

  17. Effect of pulmonary rehabilitation in cardiac output during CPET

    ANOVA comparison of cardiac output with 2 non-invasive measurement of cardiac output

    Measured: 3,6 and 12 months

  18. Evaluation of COVID-19 impact in pulmonary shunt effect

    Change in pulmonary shunt (delta kPa)

    Measured: 2,6 and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 May 2021
  2. Study start1 Jul 2020
  3. Primary completion30 Jun 2023 (estimated)
  4. Study completion30 Jun 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04881214
Sponsor's protocol ID
2020-001457
Acronym
COVISQAR
Status last verified
Sep 2022
First submitted
3 Jul 2020
Last updated
23 Sep 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Finegan O, Fonseca S, Guyomarc'h P, Morcillo Mendez MD, Rodriguez Gonzalez J, Tidball-Binz M, Winter KA; ICRC Advisory Group on the Management of COVID-19 Related Fatalities. International Committee of the Red Cross (ICRC): General guidance for the management of the dead related to COVID-19. Forensic Sci Int Synerg. 2020 Mar 31;2:129-137. doi: 10.1016/j.fsisyn.2020.03.007. eCollection 2020.

    PubMed 32412013
  • Correction to Lancet Respir Med 2020; 8: 420-22. Lancet Respir Med. 2020 Apr;8(4):e26. doi: 10.1016/S2213-2600(20)30085-0. Epub 2020 Feb 25. No abstract available.

    PubMed 32109426
  • Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020 May;15(5):700-704. doi: 10.1016/j.jtho.2020.02.010. Epub 2020 Feb 28.

    PubMed 32114094
  • Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21. No abstract available.

    PubMed 32325026
  • Guerreiro I, Bringard A, Nehme M, Guessous I, Benzakour L, Juillet De Saint Lager-Lucas A, Taboni A, Lador F. Exercise ventilatory response after COVID-19: comparison between ambulatory and hospitalized patients. Am J Physiol Lung Cell Mol Physiol. 2023 Dec 1;325(6):L756-L764. doi: 10.1152/ajplung.00142.2023. Epub 2023 Oct 24.

    PubMed 37874657

Questions about this trial

What is this clinical trial studying?

A study testing Pulmonary rehabilitation in people with Covid19 Pneumonia and Chronic Thromboembolic Pulmonary Hypertension, run by University Hospital, Geneva at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Effect of ambulatory pulmonary rehabilitation in health related quality of life (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04881214, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in